Investor Rho Ventures V, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Rho Ventures V, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2023-02-14 13G/A MRSN / Mersana Therapeutics, Inc. 1,331,187 604,213
2023-02-13 13G/A NGM / NGM Biopharmaceuticals, Inc. 3,803,270 430,783
2021-02-16 13G/A NGM / NGM Biopharmaceuticals, Inc. 3,790,666 3,803,270
2021-02-12 13G/A NGM / NGM Biopharmaceuticals, Inc. 3,784,666 3,790,666
2020-02-11 13G NGM / NGM Biopharmaceuticals, Inc. 3,784,666
2018-02-09 13G MRSN / Mersana Therapeutics, Inc. 1,331,187
2017-02-01 13G/A RLOC / ReachLocal, Inc. 0
2016-04-14 13D/A NRX / NephroGenex, Inc. 527,966
2015-01-16 13G/A RLOC / ReachLocal, Inc. 2,753,923
2015-01-07 13D/A NRX / NephroGenex, Inc. 1,052,966
2014-02-24 13D NRX / NephroGenex, Inc. 1,326,826
2013-02-04 13G/A RLOC / ReachLocal, Inc. 2,851,715